Parvoruvax®

Broad and strong protection against Parvovirus and Erysipelas
Mal Rojo / Erisipelas Parvovirus Pide un presupuesto

Parvoruvax

 

Parvoruvax for broad and strong protection against Parvovirus and Erysipelas

 

BROAD ERYSIPELAS PROTECTION

  • Against all most common swine Erysipelas strains, 1a, 1b and 2
  • Erysipelas may appear in:
    • acute form: septicaemia, hyperthermia, anorexia, erythema and death
    • sub acute /chronic forms: arthritis, endocarditis and orchitis
    • indirect reproductive failure: return to heat, abortions, embryonic death, infertility and decreased seminal quality

 

PARVOVIRUS PROTECTION

  • Against all strains of PPV causing reproductive problems to date
  • Porcine parvovirus (PPV) is the major cause of reproductive failure in swine = SMEDI (stillbirth, mummification, embryonic death and infertility)

Piglets born viremic during infection

A proper diagnosis of Parvo and Erysipelas is crucial
 

Diagnosis of Parvovirus
  • Increased percentage of mummies, irregular returns or decreased litter size, primarily in gilts, is suggestive of PPV infection
  • PPV antigen in the lungs or liver of mummified fetuses can be confirmed using immunofluorescence or PCR
  • Paired serology of samples from gilts and sows can indicate the infection
Diagnosis of Erysipelas
  • High temperature and the diamond shaped skin lesions are typical for the acute clinical disease
  • Post-mortems, culture of the organism and /or PCR from the sudden deaths confirms the diagnosis
  • Paired serology using Hemagglutination Inhibition Test or ELISA can confirm the exposure to the germ in sows or pigs

VACCINATION IS THE ONLY WAY TO CONTROL THE DISEASES

 

 

Parvoruvax: Safety. Proven safety demonstrated in research and field experience over more than 20 years

Development of systemic reactions

Development of injection site reactions

Parvoruvax  A VACCINE WITH AN EXCELLENT SAFETY PROFILE

 

INDUCES BOTH CELL MEDIATED AND HUMORAL IMMUNITY

Specific protective Cell Mediated Immunity

CMI is… CLEANING OUT INFECTION

  • mediated by IFNγ secreting cells (IFNγ-SC)
  • measured in ELISPOT test

Specific protective humoral immune response

Humoral immunity is… PROTECTING AGAINST EFFECT OF INFECTION

  • mediated by small fractions of specific antibodies
  • Erysipelas type 1a, 1b and 2 Anti-SpaA – a specific opsonizing antibody measured by SpaA  ELISA
  • PPV neutralizing antibodies (NA) measured by serum neutralization test

Parvoruvax inducesboth cell mediated and humoral immunity

The critical measures for DUAL PARVO AND ERY VACCINE PROTECTION are NA, Anti-SpaA & IFNγ-SC

Zeeuw et al., J Gen Virol 88 (2007) 420-27; Joswik et al., J Gen Virol 90 (2009) 2437-41; A.L. Ingebritson, Thesis ISU 2009; Crussard et al., IPVS/ESPHM 2016, 259

No correlation exists to general IgG ELISA´s or HI tests

 

GIVES EFFICIENT PROTECTION

 

Parvo efficacy trial

Erysipelas efficacy trial

 

Parvoruvax  PROVIDES POWERFUL AND BROAD DUAL PROTECTION AGAINST PARVOVIRUS AND ERYSIPELAS

 

 CONCLUSION ON IMMUNE RESPONSE

IFNγ-SC/CMI
– a significant and persistent cell mediated immune response against PPV and Erysipelas
(Juillard et al., IPVS 2006, 162. Piras et al., IPVS 2006,160)

Neutralizing Antibodies
– a powerful and long lasting protective humoral immune response against PPV
(Brun et al., IPVS 2006,161)

Anti-SpaA Antibodies
– a very quick and strong protective humoral immune response against Erysipelas
• Even following first primo vaccination
• Specific Anti-SpaA antibodies as well as neutralizing antibodies are linked directly to protection
• Poor correlation to general Ig tests like HI & ELISA
• Commercial ELISA’s are designed on various antigens to discover previous field infection.
(Crussard et al., IPVS/ESPHM 2016, 259)

 

VACCINATION SCHEME

 

Parvoruvax® Suspension for Injection contains Inactivated Porcine Parvovirus (K-22 strain) and Erysipelothrix rhusiopathiae (lysed bacterial cells), serotype 2. Also contains aluminium hydroxide and thiomersal. The product is indicated for active immunisation of breeding pigs (sows, gilts and boars) against porcine parvovirosis, to reduce the number of stillbirths and mummified piglets, and against erysipelas to reduce or prevent clinical symptoms. Vaccination can occasionally cause reactions of hypersensitivity in some animals, particularly in those animals sensitised by the erysipelas infection. In such case, appropriate treatment such as adrenaline should be provided. Rarely, vaccination can induce a small local reaction (<1.5 cm) at the site of injection without any effect on the health or productivity of the animal. The vaccination can cause a slight rise in body temperature (<0.2°C) that returns to normal values from 1 to 2 days after vaccination without any consequence to the health or productivity of the animal. Primary vaccination against porcine parvovirosis should not be carried out in the presence of maternally derived antibodies. Only healthy animals should be vaccinated. The vaccine is safe for use during pregnancy and lactation. However, avoid vaccination during the 3 weeks following service mating. Withdrawal periods: Zero days. Pharmaceutical precautions: Use immediately after opening. Store between 2°C and 8°C, protected from light. For more details, see the SPC applicable in your country. This page contains information on a veterinary biological product sold in several different countries and areas where it may be subject to different regulatory approvals. Ceva gives no guarantee that the details presented are correct with respect to all locations. In addition, the safety and efficacy data and the withholding periods may be different depending on local regulations. Please consult your veterinarian for further information.

CevaCeva Santé Animale
10, av. de La Ballastière
33500 Libourne

¿Te interesa este producto?

Pide un presupuesto


regístrate con el correo electrónico